Cancer Research Technology
Log in Register
Menu

Anti-MCSP [LHM 2]

Info

Catalogue Number 151118
Applications FACS IHC IF IP WB ICC
Antigen/Gene or Protein Targets Melanoma associated Chondroitin Sulphate Proteoglycan (MCSP or NG2)
Reactivity Human
Relevance Monoclonal antibody against MCSP melanoma marker.

Background and Research Application
MCSP is a chondroitin surface proteoglycan, involved in stabilizing cell-substratum interactions during early events of cell spreading. MCSP is an integral membrane chondroitin sulphate proteoglycan expressed by human malignant melanoma cells.
Anti-MCSP (LHM2) antibody is a very good marker for melanoma (>90% stained). LHM2 also stains basal cell carcinomas and subpopulation of basal keratinocytes. LHM2 can be used as a diagnostic panel for immunopathology of malignant melanoma and potential candidates for immunoimaging and immunotherapy of disseminated melanoma. Potential applications of the LHM2 antibody include use for separation/isolation of epidermal stem cells, detection of stem cells in skin biopsies or epithelial cell cultures and optimisation of culture conditions to retain epidermal stem cell population in in vitro cultures.
Host Mouse
Immunogen A 375P cells crude extract.
Immunogen UniProt ID Q6UVK1
Subclass IgG1 kappa
Molecular Weight (kDa) 240
Myeloma Used NS0
Recommended Growing Conditions DMEM + 5% FCS
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
The originators of this antibody report that the MCSP is a cell surface marker specific for epidermal stem cells (J. Invest. Dermatol. in press).

Concentration
1mg/ml as standard
Research Area Adhesion, Cancer, Cell Type or Organelle Marker, Neurobiology

References

There are 10 reference entries for this reagent.

View All References

References: 10 entries

Li et al. 2019. Theranostics. 9(17):5105-5121. PMID: 31410204.

Arrigoni et al. 2016. Adv Healthc Mater. 5(13):1617-26. PMID: 27191352.

Loibl et al. 2014. Biomed Res Int. 2014:395781. PMID: 24563864.

IF ICC

Somaiah et al. 2012. Clin Cancer Res. 18(19):5479-88. PMID: 22855580.

Somaiah et al. 2012. Clin Cancer Res. 18(19):5479-88. PMID: 22855580.

IHC

Kinney et al. 2012. Ann Neurol. 71(3):397-406. PMID: 22451205.

Pierce et al. 2011. Aging Cell. 10(6):1032-7. PMID: 21943306.

Ghali et al. 2004. J Invest Dermatol. 122(2):433-42. PMID: 15009727.

Kupsch et al. 1999. Clin Cancer Res. 5(4):925-31. PMID: 10213230.

Kupsch et al. 1995. Melanoma Res. 5(6):403-11. PMID: 8589614.


Add a reference

References: 10 entries

Li et al. 2019. Theranostics. 9(17):5105-5121. PMID: 31410204.

Arrigoni et al. 2016. Adv Healthc Mater. 5(13):1617-26. PMID: 27191352.

Loibl et al. 2014. Biomed Res Int. 2014:395781. PMID: 24563864.

IF ICC

Somaiah et al. 2012. Clin Cancer Res. 18(19):5479-88. PMID: 22855580.

Somaiah et al. 2012. Clin Cancer Res. 18(19):5479-88. PMID: 22855580.

IHC

Kinney et al. 2012. Ann Neurol. 71(3):397-406. PMID: 22451205.

Pierce et al. 2011. Aging Cell. 10(6):1032-7. PMID: 21943306.

Ghali et al. 2004. J Invest Dermatol. 122(2):433-42. PMID: 15009727.

Kupsch et al. 1999. Clin Cancer Res. 5(4):925-31. PMID: 10213230.

Kupsch et al. 1995. Melanoma Res. 5(6):403-11. PMID: 8589614.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor